Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Identifieur interne : 001810 ( Main/Exploration ); précédent : 001809; suivant : 001811Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Auteurs : Rodney U. Anderson [États-Unis] ; Scott Macdiarmid ; Sherron Kell ; James H. Barada ; Scott Serels ; Roger P. GoldbergSource :
- International urogynecology journal and pelvic floor dysfunction ; 2006.
English descriptors
- KwdEn :
- Adult, Aged, Benzhydryl Compounds (adverse effects), Benzhydryl Compounds (pharmacology), Cresols (adverse effects), Cresols (pharmacology), Demography, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Mandelic Acids (adverse effects), Mandelic Acids (pharmacology), Middle Aged, Muscarinic Antagonists (adverse effects), Muscarinic Antagonists (pharmacology), Patient Dropouts, Patient Participation, Phenylpropanolamine (adverse effects), Phenylpropanolamine (pharmacology), Tolterodine Tartrate, Treatment Outcome, Urinary Bladder, Overactive (drug therapy), Urinary Incontinence, Urge (drug therapy).
- MESH :
- chemical , adverse effects : Benzhydryl Compounds, Cresols, Mandelic Acids, Muscarinic Antagonists, Phenylpropanolamine.
- chemical , pharmacology : Benzhydryl Compounds, Cresols, Mandelic Acids, Muscarinic Antagonists, Phenylpropanolamine.
- drug therapy : Urinary Bladder, Overactive, Urinary Incontinence, Urge.
- Adult, Aged, Demography, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Middle Aged, Patient Dropouts, Patient Participation, Tolterodine Tartrate, Treatment Outcome.
Abstract
The efficacy and the tolerability of extended-release oxybutynin chloride, 10 mg daily, and extended-release tolterodine tartrate, 4 mg daily, in women with or without prior anticholinergic treatment for overactive bladder (OAB) were compared in a post-hoc analysis of data from the Overactive Bladder: Performance of Extended Release Agents (OPERA) trial. The patient population and study methods have been described previously (Diokno et al., for the OPERA Study Group, Mayo Clin Proc 78:687-695, 2003). Among the group with anticholinergic experience, extended-release oxybutynin was significantly more effective than extended-release tolterodine in reducing micturition frequency at last observation (p=0.052). Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23.6 vs 15.1%, p=0.038). In addition, among patients completing a full 12 weeks of oxybutynin treatment, significantly greater reductions were observed compared with those taking tolterodine on the primary efficacy variable, number of urge incontinence episodes (p=0.049), and the combined total of urge and non-urge episodes (p=0.012), although the differences between treatment groups were not significant at last observation. In the anticholinergic-naïve group, efficacy and tolerability outcomes were similar across treatments, except that oxybutynin was associated with a significantly lower frequency of micturition at last observation (p=0.035). No efficacy differences favoring tolterodine were observed, and tolerability of the treatments was comparable. Dry mouth (mostly mild to moderate in severity) was reported significantly more often among participants taking extended-release oxybutynin than extended-release tolterodine (32.2 vs 19.2%, p=0.004), but only among those with previous anticholinergic experience. Discontinuation rates were comparably low across groups. The results demonstrate the appropriateness of initiating treatment for OAB with extended-release oxybutynin, particularly in women presenting with incontinence.
DOI: 10.1007/s00192-005-0057-7
PubMed: 16724169
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000491
- to stream PubMed, to step Curation: 000491
- to stream PubMed, to step Checkpoint: 000469
- to stream Ncbi, to step Merge: 000393
- to stream Ncbi, to step Curation: 000393
- to stream Ncbi, to step Checkpoint: 000393
- to stream Main, to step Merge: 001843
- to stream Main, to step Curation: 001810
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.</title><author><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305, USA. rua@stanford.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Macdiarmid, Scott" sort="Macdiarmid, Scott" uniqKey="Macdiarmid S" first="Scott" last="Macdiarmid">Scott Macdiarmid</name></author><author><name sortKey="Kell, Sherron" sort="Kell, Sherron" uniqKey="Kell S" first="Sherron" last="Kell">Sherron Kell</name></author><author><name sortKey="Barada, James H" sort="Barada, James H" uniqKey="Barada J" first="James H" last="Barada">James H. Barada</name></author><author><name sortKey="Serels, Scott" sort="Serels, Scott" uniqKey="Serels S" first="Scott" last="Serels">Scott Serels</name></author><author><name sortKey="Goldberg, Roger P" sort="Goldberg, Roger P" uniqKey="Goldberg R" first="Roger P" last="Goldberg">Roger P. Goldberg</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1007/s00192-005-0057-7</idno><idno type="RBID">pubmed:16724169</idno><idno type="pmid">16724169</idno><idno type="wicri:Area/PubMed/Corpus">000491</idno><idno type="wicri:Area/PubMed/Curation">000491</idno><idno type="wicri:Area/PubMed/Checkpoint">000469</idno><idno type="wicri:Area/Ncbi/Merge">000393</idno><idno type="wicri:Area/Ncbi/Curation">000393</idno><idno type="wicri:Area/Ncbi/Checkpoint">000393</idno><idno type="wicri:Area/Main/Merge">001843</idno><idno type="wicri:Area/Main/Curation">001810</idno><idno type="wicri:Area/Main/Exploration">001810</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.</title><author><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305, USA. rua@stanford.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Macdiarmid, Scott" sort="Macdiarmid, Scott" uniqKey="Macdiarmid S" first="Scott" last="Macdiarmid">Scott Macdiarmid</name></author><author><name sortKey="Kell, Sherron" sort="Kell, Sherron" uniqKey="Kell S" first="Sherron" last="Kell">Sherron Kell</name></author><author><name sortKey="Barada, James H" sort="Barada, James H" uniqKey="Barada J" first="James H" last="Barada">James H. Barada</name></author><author><name sortKey="Serels, Scott" sort="Serels, Scott" uniqKey="Serels S" first="Scott" last="Serels">Scott Serels</name></author><author><name sortKey="Goldberg, Roger P" sort="Goldberg, Roger P" uniqKey="Goldberg R" first="Roger P" last="Goldberg">Roger P. Goldberg</name></author></analytic><series><title level="j">International urogynecology journal and pelvic floor dysfunction</title><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Benzhydryl Compounds (adverse effects)</term><term>Benzhydryl Compounds (pharmacology)</term><term>Cresols (adverse effects)</term><term>Cresols (pharmacology)</term><term>Demography</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Female</term><term>Humans</term><term>Mandelic Acids (adverse effects)</term><term>Mandelic Acids (pharmacology)</term><term>Middle Aged</term><term>Muscarinic Antagonists (adverse effects)</term><term>Muscarinic Antagonists (pharmacology)</term><term>Patient Dropouts</term><term>Patient Participation</term><term>Phenylpropanolamine (adverse effects)</term><term>Phenylpropanolamine (pharmacology)</term><term>Tolterodine Tartrate</term><term>Treatment Outcome</term><term>Urinary Bladder, Overactive (drug therapy)</term><term>Urinary Incontinence, Urge (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzhydryl Compounds</term><term>Cresols</term><term>Mandelic Acids</term><term>Muscarinic Antagonists</term><term>Phenylpropanolamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzhydryl Compounds</term><term>Cresols</term><term>Mandelic Acids</term><term>Muscarinic Antagonists</term><term>Phenylpropanolamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Urinary Bladder, Overactive</term><term>Urinary Incontinence, Urge</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Demography</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Patient Dropouts</term><term>Patient Participation</term><term>Tolterodine Tartrate</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy and the tolerability of extended-release oxybutynin chloride, 10 mg daily, and extended-release tolterodine tartrate, 4 mg daily, in women with or without prior anticholinergic treatment for overactive bladder (OAB) were compared in a post-hoc analysis of data from the Overactive Bladder: Performance of Extended Release Agents (OPERA) trial. The patient population and study methods have been described previously (Diokno et al., for the OPERA Study Group, Mayo Clin Proc 78:687-695, 2003). Among the group with anticholinergic experience, extended-release oxybutynin was significantly more effective than extended-release tolterodine in reducing micturition frequency at last observation (p=0.052). Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23.6 vs 15.1%, p=0.038). In addition, among patients completing a full 12 weeks of oxybutynin treatment, significantly greater reductions were observed compared with those taking tolterodine on the primary efficacy variable, number of urge incontinence episodes (p=0.049), and the combined total of urge and non-urge episodes (p=0.012), although the differences between treatment groups were not significant at last observation. In the anticholinergic-naïve group, efficacy and tolerability outcomes were similar across treatments, except that oxybutynin was associated with a significantly lower frequency of micturition at last observation (p=0.035). No efficacy differences favoring tolterodine were observed, and tolerability of the treatments was comparable. Dry mouth (mostly mild to moderate in severity) was reported significantly more often among participants taking extended-release oxybutynin than extended-release tolterodine (32.2 vs 19.2%, p=0.004), but only among those with previous anticholinergic experience. Discontinuation rates were comparably low across groups. The results demonstrate the appropriateness of initiating treatment for OAB with extended-release oxybutynin, particularly in women presenting with incontinence.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Barada, James H" sort="Barada, James H" uniqKey="Barada J" first="James H" last="Barada">James H. Barada</name><name sortKey="Goldberg, Roger P" sort="Goldberg, Roger P" uniqKey="Goldberg R" first="Roger P" last="Goldberg">Roger P. Goldberg</name><name sortKey="Kell, Sherron" sort="Kell, Sherron" uniqKey="Kell S" first="Sherron" last="Kell">Sherron Kell</name><name sortKey="Macdiarmid, Scott" sort="Macdiarmid, Scott" uniqKey="Macdiarmid S" first="Scott" last="Macdiarmid">Scott Macdiarmid</name><name sortKey="Serels, Scott" sort="Serels, Scott" uniqKey="Serels S" first="Scott" last="Serels">Scott Serels</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001810 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001810 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16724169
|texte= Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16724169" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |